Ontak

FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)

...cal trial to confirm the clinical effectiveness of ontak in certain patients with cutaneous T-cell lymphoma (CTCL). ontak is indicated for the treatment of patients with pe...t of the IL-2 receptor. The safety and efficacy of ontak in patients with CTCL whose malignant cells do not...

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

... with cutaneous T-cell lymphoma (CTCL) showed that ontak was more than twice as effective as placebo in eli...American Society of Clinical Oncology (ASCO). ontak is indicated for the treatment of patients with pe...onent of the IL-2 receptor have not been examined. ontak was granted accelerated approval in February 1999....

Ontak in other areas

Ontak (Denileukin Diftitox) Drug Information: Uses, Side Effects, Drug ...

Learn about the prescription medication Ontak (Denileukin Diftitox), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.

ONTAK

ONTAK is supplied in single use vials as a sterile, frozen solution intended for ... Each 2 mL vial of ONTAK contains 300 mcg of ...

Ontak, Denileukin Diftitox - Chemotherapy Drugs, Chemo Drug Side Effects

Ontak is the trade name for Denileukin Diftitox. Ontak is a targeted therapy. ... professionals may use the trade name Ontak when referring to the generic drug ...

FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) To Full ...

... priority review a supplemental biologics license application (sBLA) for ONTAK(R) ... ONTAK is indicated for the treatment of patients with persistent or recurrent ...

ONTAK(R) (denileukin Diftitox) Achieves 49.1% Overall Response Rate In ...

Preliminary results of the largest randomized, placebo-controlled clinical trial ever conducted in patients with cutaneous T-cell lymphoma (CTCL) showed that ONTAK ...

Success Story: Ontak (NSC 697979)

1998 Ontak (NSC 697979), also known as denileukin diftitox or interleukin-2 (IL ... Ontak is one of four NCDDG-developed agents approved by the FDA since the ...